CompletedNot Applicable

A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation

United States48 participantsStarted 2024-10-21

Plain-language summary

This was a single-center, double-blinded, randomized, controlled cosmetic clinical trial to investigate the efficacy and tolerance of dark spot corrector serum and regimen skincare products when used over the course of 16 weeks by women with clinically determined moderate discrete hyperpigmentation (solar lentigines \[age spots/sun spots\]) on the global face, and self-perceived very bothersome hyperpigmentation (darkening), including spots, on the global face.

Who can participate

Age range25 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Having been diagnosed with known allergies to skin care products.
✕. Having a known reactivity to niacinamide, sunflower seed, coconut, rosemary, barley, goji, sandalwood, licorice root, radish root, beeswax, and/or yeast.
✕. Breastfeeding, pregnant, or planning to become pregnant during the study according to subject self-report.
✕. Having a history of skin cancer within the past 5 years.
✕. Currently using oral or topical prescription medications for acne such as doxycycline, minocycline, clindamycin, Bactrim, tetracycline, erythromycin, azelaic acid, benzoyl peroxide, Dapsone, or sodium sulfacetamide.

What they're measuring

Measurement of Clinical Efficacy Parameters by Clinical Grader

Timeframe: Baseline, week 2, 4, 8, 12, and 16

Trial details

NCT IDNCT07468175

SponsorRevision Skincare

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-03-13

View on ClinicalTrials.gov More Hyperpigmentation trials